Jenny Shan

1.9k citations
26 papers · 1.4k · h-index 13

Impact in

  • Hematology top 0.5%
    • Chronic Myeloid Leukemia Treatments
    • Acute Myeloid Leukemia Research
  • Genetics top 1%
    • Chronic Lymphocytic Leukemia Research
    • Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

  • Hematology 25
    • Chronic Myeloid Leukemia Treatments 21
    • Acute Myeloid Leukemia Research 4
    • Blood Coagulation and Thrombosis Mechanisms 1
  • Genetics 15
    • Chronic Lymphocytic Leukemia Research 15
Co-authors
Hagop M. Kantarjian (24 shared papers)Jörge E. Cortes (24 shared papers)Guillermo Garcia‐Manero (19 shared papers)Susan O’Brien (19 shared papers)Farhad Ravandi (14 shared papers)Mary Beth Rios (10 shared papers)Stefan Faderl (8 shared papers)Elias Jabbour (13 shared papers)
Journals
Blood (18 papers)Cancer (4 papers)Clinical Cancer Research (1 paper)Advances in Therapy (1 paper)Journal of Clinical Oncology (1 paper)
Partner nations
United StatesFranceSweden

In The Last Decade

Jenny Shan

25 papers receiving 1.3k citations

Peers

Jenny Shan
Comparison fields: 5 of 48
  • Hematology 1.2k
  • Genetics 735
  • Rheumatology 467
  • Pathology and Forensic Medicine 78
  • Oncology 113
Replace Manuel Ayala with:
Manuel Ayala Mexico
Agnès Guerci‐Bresler France
Jorge Milone Argentina
Anthony K. Mills Australia
Carolina Pavlovsky Argentina
Rick E. Blakesley United States
Laurie Letvak United States
Jiří Mayer Czechia
Beatriz Moiraghi Argentina
D-W Kim Germany
Jenny Shan relative to Manuel Ayala Mexico Manuel Ayala's profile →
Citations per field
00.5×1.5×2×2.5×
Manuel Ayala · 1×
Citations per year

Countries citing papers authored by Jenny Shan

Since Specialization
Citations

This map shows the geographic impact of Jenny Shan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jenny Shan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jenny Shan more than expected).

Fields of papers citing papers by Jenny Shan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jenny Shan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jenny Shan. The network helps show where Jenny Shan may publish in the future.

Co-authors

The 25 scholars most cited alongside Jenny Shan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jenny Shan Line = papers co-authored together Jenny Shan links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
Blood ·Hagop M. Kantarjian, Susan O’Brien, Elias Jabbour, Guillermo Garcia‐Manero, Alfonso Quintás‐Cardama, Jenny Shan, Mary Beth Rios, Farhad Ravandi, Stefan Faderl, Tapan M. Kadia, Gautam Borthakur, Xuelin Huang, Richard E. Champlin, Moshe Talpaz, Jörge E. Cortes
2012246
2
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
Cancer ·Elias Jabbour, Guillermo Garcia‐Manero, Nicolas Batty, Jenny Shan, Susan O’Brien, Jörge E. Cortes, Farhad Ravandi, Jean‐Pierre J. Issa, Hagop M. Kantarjian
2010222
3
Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate
Clinical Cancer Research ·Jörge E. Cortes, Moshe Talpaz, Susan O’Brien, Dan Jones, Rajyalakshmi Luthra, Jenny Shan, Francis J. Giles, Stefan Faderl, Srđan Verstovšek, Guillermo Garcia‐Manero, Mary Beth Rios, Hagop M. Kantarjian
2005209
4
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
Blood ·Elias Jabbour, Hagop M. Kantarjian, Dan Jones, Jenny Shan, Susan O’Brien, Neeli Reddy, William G. Wierda, Stefan Faderl, Guillermo Garcia‐Manero, Srđan Verstovšek, Mary Beth Rios, Jörge E. Cortes
2008128
5
The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
Blood ·Elias Jabbour, Hagop M. Kantarjian, Susan O’Brien, Jenny Shan, Alfonso Quintás‐Cardama, Stefan Faderl, Guillermo Garcia‐Manero, Farhad Ravandi, Mary Beth Rios, Jörge E. Cortes
2011109
6
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
Blood ·Constantine S. Tam, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Gautam Borthakur, Susan O’Brien, Farhad Ravandi, Jenny Shan, Jörge E. Cortes
200890
7
Staging of chronic myeloid leukemia in the imatinib era
Cancer ·Jörge E. Cortes, Moshe Talpaz, Susan O’Brien, Stefan Faderl, Guillermo Garcia‐Manero, Alessandra Ferrajoli, Srđan Verstovšek, Mary Beth Rios, Jenny Shan, Hagop M. Kantarjian
200685
8
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
Blood ·Elias Jabbour, Hagop M. Kantarjian, Susan O’Brien, Jenny Shan, Guillermo Garcia‐Manero, William G. Wierda, Farhad Ravandi, Gautam Borthakur, Mary Beth Rios, Jörge E. Cortes
201057
9
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia
Cancer ·Jörge E. Cortes, Alfonso Quintás-Cardama, Dan Jones, Farhad Ravandi, Guillermo Garcia‐Manero, Srđan Verstovšek, Charles Koller, Jody Hiteshew, Jenny Shan, Susan O’Brien, Hagop M. Kantarjian
201037
10
Impact of Treatment End Point Definitions on Perceived Differences in Long-Term Outcome With Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
Journal of Clinical Oncology ·Hagop M. Kantarjian, Susan O’Brien, Elias Jabbour, Jenny Shan, Farhad Ravandi, Tapan M. Kadia, Stefan Faderl, Guillermo Garcia‐Manero, Gautam Borthakur, Jörge E. Cortes
201136
11
Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis
Advances in Therapy ·Barry Jacobson, Virendra Rambiritch, Dara Paek, Tobias Sayre, Poobalan Naidoo, Jenny Shan, Rory Leisegang
201930
12
Activity of 9‐nitro‐camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia
Cancer ·Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Susan O’Brien, Elias Jabbour, Francis J. Giles, Farhad Ravandi, Stefan Faderl, Sherry Pierce, Jenny Shan, Srđan Verstovšek, Jörge E. Cortes
200623
13
The Clinical Significance of Achieving Different Levels of Cytogenetic Response in Patients With Chronic Phase Chronic Myeloid Leukemia After Failure to Front-Line Therapy: Is Complete Cytogenetic Response the Only Desirable Endpoint?
Clinical Lymphoma Myeloma & Leukemia ·Jörge E. Cortes, Alfonso Quintás‐Cardama, Elias Jabbour, Susan O’Brien, Srđan Verstovšek, Gautam Borthakur, Farhad Ravandi, Guillermo Garcia‐Manero, Elizabeth M. Burton, Jenny Shan, Hagop M. Kantarjian
201114
14
Better Molecular Response to Imatinib for Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Carrying the b3a2 Transcript Compared to b2a2.
Blood ·Arturo Vega-Ruiz, Hagop M. Kantarjian, Jenny Shan, William G. Wierda, Jan A. Burger, Srđan Verstovšek, Guillermo Garcia‐Manero, Jörge E. Cortes
200711
15
Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP).
Blood ·Jörge E. Cortes, Gautam Borthakur, Susan O’Brien, Dan Jones, Elias Jabbour, Farhad Ravandi, Charles Koller, Brenda Walker, Jenny Shan, Hagop M. Kantarjian
200910
16
Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure.
Blood ·Elias Jabbour, Hagop M. Kantarjian, Susan O’Brien, Jenny Shan, Guillermo Garcia‐Manero, William G. Wierda, Farhad Ravandi, Gautam Borthakur, Mary Beth Rios, Jörge E. Cortes
20099
17
Efficacy of Nilotinib in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP).
Blood ·Jörge E. Cortes, Susan O’Brien, Dan Jones, Elias Jabbour, Marina Konopleva, Alessandra Ferrajoli, Tapan M. Kadia, Gautam Borthakur, Denise Stigliano, Jenny Shan, Hagop M. Kantarjian
20098
18
Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.
Blood ·Dushyant Verma, Hagop M. Kantarjian, Jenny Shan, Susan O’Brien, Amit Kumar Verma, Elias Jabbour, Srđan Verstovšek, Tapan M. Kadia, Mary Beth Rios, Jörge E. Cortes
20098
19
Delayed Achievement of Molecular Responses Is Associated with Increased Risk of Progression among Patients (pts) with Chronic Myelogenous Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib (IM).
Blood ·Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Dan Jones, Guillermo Garcia‐Manero, Susan O’Brien, Jenny Shan, Farhad Ravandi, William G. Wierda, Jörge E. Cortes
20068
20
The Achievement of a 3-Month Complete Cytogenetic Response (3-mo CCyR) to Second Generation (2nd) Tyrosine Kinase Inhibitors (TKI) Post Imatinib Failure Is the Only Predictive Factor for Event-Free (EFS) and Overall Survival (OS)
Blood ·Elias Jabbour, Hagop M. Kantarjian, Jenny Shan, Susan O’Brien, Alfonso Quintás‐Cardama, Guillermo Garcia‐Manero, Jörge E. Cortes
20104

About Jenny Shan

Jenny Shan is a scholar working on Hematology, Genetics, Rheumatology, Pathology and Forensic Medicine and Molecular Biology, having authored 26 papers that have together received 1.4k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (21 papers), Chronic Lymphocytic Leukemia Research (15 papers), Eosinophilic Disorders and Syndromes (9 papers), Acute Myeloid Leukemia Research (4 papers), Acute Lymphoblastic Leukemia research (2 papers), Lymphoma Diagnosis and Treatment (2 papers), Gastrointestinal Tumor Research and Treatment (1 paper) and Blood Coagulation and Thrombosis Mechanisms (1 paper). The work is most often cited by research in Hematology (1.2k citations), Genetics (735 citations), Rheumatology (467 citations), Pathology and Forensic Medicine (78 citations) and Oncology (113 citations). Jenny Shan has collaborated with scholars based in United States, France and Sweden. Frequent co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Guillermo Garcia‐Manero, Susan O’Brien, Farhad Ravandi, Mary Beth Rios, Stefan Faderl, Elias Jabbour, Srđan Verstovšek and Moshe Talpaz. Their work appears in journals such as Blood, Cancer, Clinical Cancer Research, Advances in Therapy and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Manuel AyalaBreakdown of academic impact, for papers by Agnès Guerci‐BreslerBreakdown of academic impact, for papers by Jorge MiloneBreakdown of academic impact, for papers by Anthony K. MillsBreakdown of academic impact, for papers by Carolina PavlovskyBreakdown of academic impact, for papers by Rick E. BlakesleyBreakdown of academic impact, for papers by Laurie LetvakBreakdown of academic impact, for papers by Jiří MayerBreakdown of academic impact, for papers by Beatriz MoiraghiBreakdown of academic impact, for papers by D-W Kim